News from spherix global insights A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 06, 2021, 08:00 ET Oral Gepants Have Disrupted Acute Migraine Management and Look Next to Transform Preventive Treatment, According to Both Primary Care Physicians and Specialists

Both AbbVie's (formerly Allergan, an AbbVie company) Ubrelvy and Biohaven's Nurtec ODT are viewed by primary care physicians (PCPs) as strong...

May 05, 2021, 08:00 ET Spherix Global Insights Finds That Pipeline Therapies for Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis Will Need to Strike a Balance Between Liver Fat Reduction, Fibrosis Improvement, and Patient Safety as They Seek FDA Approval

Spherix recently surveyed 99 US gastroenterologists and 23 hepatologists and conducted ten qualitative interviews to assess the current and future...

Apr 28, 2021, 08:00 ET New Spherix Global Insights' Patient Audit Highlights Key Differences Between Dermatologists' and Rheumatologists' Management of Psoriatic Arthritis, Focusing on Patients Recently Switched Between Advanced Systemic Treatment Brands

The past five or so years have seen a flurry of US biologic approvals for the treatment of psoriasis (PSO), resulting in an era of unprecedented...

Apr 07, 2021, 14:43 ET Specialty Physicians Point to Permanent Changes Introduced by the COVID-19 Pandemic, Highlighting the Challenges that Lie Ahead for Pharmaceutical Manufacturers

Since late March 2020, Spherix has been surveying specialty physicians (dermatologists, gastroenterologists, nephrologists, neurologists, and...

Mar 31, 2021, 08:00 ET Bristol Myers Squibb's Zeposia and Biogen's Vumerity Place Competitive Pressure on Established Brands in the Multiple Sclerosis Switch Segment, According to Spherix Global Insights

Biogen's Tecfidera, Novartis' Gilenya, and Genentech's Ocrevus have all faced extensive competitive pressure over the past year due to launches of...

Mar 24, 2021, 13:03 ET Upcoming Oral, Small Molecule Agents Have the Potential to Leapfrog Existing Biologic Treatment and Become Foundational Inflammatory Bowel Disease Therapies

Spherix recently surveyed 100 US gastroenterologists and followed up with seven qualitative interviews (including an industry key opinion leader) in...

Mar 22, 2021, 12:44 ET Groundbreaking New Research from Spherix Global Insights Leverages More Than 1,100 Patient Charts to Provide Insights on IgA Nephropathy, Focal Segmental Glomerulosclerosis, and Alport Syndrome

Glomerular diseases, including IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), and Alport Syndrome, among others, together amount...

Mar 12, 2021, 07:00 ET On the Heels of Recent FDA Approvals, GlaxoSmithKline's BENLYSTA (belimumab) and Aurinia Pharmaceuticals' LUPKYNIS (voclosporin) Emerge as Practical and Effective Tools in the Treatment of Lupus Nephritis

The Lupus Foundation of America estimates that 1.5 million Americans, and at least five million people worldwide, have a form of lupus.[1] As many as ...

Mar 04, 2021, 13:05 ET As SGLT2 Inhibitors Create Increased Market Complexities for Chronic Kidney Disease Non-Dialysis Patients, How Quickly Will Patient Care Evolve - If at All?

Chronic kidney disease (CKD) patients experience a wide range of comorbidities and risks associated with their disease, such as diabetic...

Feb 17, 2021, 07:30 ET Tides Continue to Shift as Novartis' Cosentyx and Eli Lilly's Taltz Experience Early Success in Non-Radiographic Axial Spondyloarthritis

Approved just two weeks apart in June of last year for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA), in-class competitors,...

Feb 16, 2021, 14:27 ET Spherix Global Insights Releases 2020 Corporate Highlights and Shares Outlook for 2021

Spherix Global Insights ("Spherix") is a hyper-focused market intelligence firm that leverages its own independent data and expertise to provide...

Feb 12, 2021, 05:00 ET The Impact of COVID-19 on Specialty Physician Practices is Far from Over, Leaving Pharmaceutical Companies to Assess Whether Traditional Promotional Efforts Will Ever Revert to the Pre-COVID Era

Ten months after the doors closed in response to the COVID-19 pandemic, a survey of 266 US specialty physicians conducted by Spherix Global Insights...

Feb 11, 2021, 08:10 ET Biogen's Vumerity and Bristol Myers Squibb's Zeposia Show Signs of Early First-Line Success Among Multiple Sclerosis Patients Due to Tolerability and Onboarding Advantages Over Established Agents

With the recent additions of Novartis' Mayzent, Bristol Myers Squibb's Zeposia, and Biogen's Vumerity to the multiple sclerosis (MS) market in the...

Feb 10, 2021, 08:10 ET Recent Otezla Growth: A Result of the Amgen Acquisition or Benefiting from the Pandemic?

Despite the potential for setbacks brought forth by the COVID-19 pandemic, Amgen recently reported strong year-over-year growth for their newly...

Jan 29, 2021, 07:25 ET Spherix Global Insights Introduces New Service Focusing on Recent Launches in Expanding Immunology, Nephrology, and Neurology Markets

Spherix Global Insights, a leading market intelligence firm specializing in select dermatology, gastroenterology, nephrology, neurology, and...

Jan 25, 2021, 17:45 ET Unmet Need in Lupus Nephritis Finally Addressed with New FDA Approvals for GlaxoSmithKline's BENLYSTA (belimumab) and Aurinia Pharmaceuticals' LUPKYNIS (voclosporin)

According to a survey of more than 200 US rheumatologists and nephrologists in mid-2020, the unmet need for new treatments for lupus nephritis (LN)...

Jan 21, 2021, 07:30 ET New Research on Emerging Markets in Dermatology Reveals Vast Potential for Pipeline Agents

Spherix recently surveyed 101 US dermatologists and followed up with eleven qualitative interviews (including two with industry key opinion leaders)...

Jan 20, 2021, 05:00 ET Takeda's Entyvio SC and Celltrion's Remsima SC EU5 Launches Have Benefitted from Parent Brand Reputation, New Clinical Data, and COVID-19 Restraints, According to Spherix Global Insights

Two 2020 European Medical Agency (EMA) approvals, Takeda's Entyvio SC and Celltrion Healthcare's infliximab biosimilar, Remsima SC, have captured...

Nov 17, 2020, 08:00 ET IL-23 Inhibitors Take Over the US Psoriasis Switching Market at the Expense of the IL-17 and TNF Inhibitors

The 2020 audit included in Spherix's RealWorld Dynamix™: Biologic/Small Molecule Switching in Psoriasis (US) service focuses on a critical facet of...

Nov 09, 2020, 05:00 ET Increased Biosimilar Prescribing and New Subcutaneous Formulations Are Poised to Impact Biologic Switching in the EU Inflammatory Bowel Disease Market, According to Spherix Global Insights

According to the latest report published as part of Spherix's RealWorld Dynamix™: Biologic/Small Molecule Switching in IBD (EU) service, EU...

Nov 05, 2020, 09:15 ET Private Equity Consolidation in Gastroenterology Practices: The Near-Term Outlook and What it Means for Pharma Companies

Spherix Global Insights, a market intelligence firm providing independent coverage of specialty markets such as inflammatory bowel disease (IBD), and ...

Nov 02, 2020, 15:07 ET Nephrologists Attending the American Society of Nephrology Virtual Meeting Point to New Data on the SGLT2 Inhibitor Class as Being the Most Compelling Presented at the Conference hl2According to Spherix Global Insights, nephrologists overwhelmingly chose the DAPA-CKD trial as the most compelling among the eight presented during the oral abstract session, "High Impact Clinical Trials"

With virtual conferences being the standard for the foreseeable future, Spherix Global Insights sought to gather feedback from attendees of ASN...

Oct 29, 2020, 15:03 ET Eosinophilic Esophagitis, a Complex, Chronic Autoimmune Condition, Awaits FDA-Approved Therapies, Potentially Including a Biologic Option, According to Spherix Global Insights

Spherix recently surveyed 103 US gastroenterologists and followed up with ten qualitative interviews (including two with industry key opinion...

Oct 27, 2020, 07:55 ET Genentech's Ocrevus Dominates the Progressive Multiple Sclerosis Market, Although Emerging Agents Could Threaten its Long-Term Reign, According to Patient Chart Data from Spherix Global Insights

While the segment of multiple sclerosis (MS) patients with progressive disease remains underserved, numerous recent approvals for relapsing MS (RMS)...

Oct 22, 2020, 13:00 ET Spherix Global Insights Climbs the Ranks on Two Lists Recognizing Greater Philadelphia's Fastest Growing Companies

In their second year of eligibility, Spherix Global Insights, a market intelligence firm focusing on immunology, nephrology, and neurology markets,...